News
- Author:
- Neil Osterweil
Publish date: December 13, 2012
Major Finding: In an efficacy cohort of 110 patients with relapsed or refractory mantle cell lymphoma, 22% had a complete response and 46% a parti...
News
- Author:
- Neil Osterweil
Publish date: December 12, 2012
Major Finding: In a study cohort with a second-generation formulation of avatrombopag, 9 of 21 patients on a 10-mg daily dose (42.9%) had a platel...
News
- Author:
- Neil Osterweil
Publish date: December 12, 2012
Major Finding: In a phase IIIb randomized study, 89% of lamivudine-resistant patients with HBV who received tenofovir alone met the primary end po...
News
- Author:
- Neil Osterweil
Publish date: December 11, 2012
Major Finding: Among patients with HIV and hepatitis C coinfection, 74% of those treated with telaprevir in combination with pegylated interferon ...
News
- Author:
- Neil Osterweil
Publish date: December 11, 2012
Major Finding: Median overall survival in patients who were positive for the FLT3-ITD mutation and received a transplant was 33.3 weeks, vs.
News
- Author:
- Neil Osterweil
Publish date: December 11, 2012
Major Finding: At 16 weeks of therapy, 45% of treatment-experienced cirrhotic patients on a combination of telaprevir, pegylated interferon, and r...
News
- Author:
- Neil Osterweil
Publish date: December 10, 2012
Major Finding: In this study, 2.8% of patients treated to a hematocrit target of less than 45% experienced one or more events in a composite prima...
News
- Author:
- Neil Osterweil
Publish date: December 10, 2012
Major Finding: In heavily pretreated patients with relapsed or refractory chronic-phase CML, ponatinib produced a major cytogenetic response in 56...
News
- Author:
- Neil Osterweil
Publish date: December 10, 2012
Major Finding: The 5-year overall survival among children with B-cell lineage ALL treated without daunorubicin in the induction regimen was 98%, c...
News
- Author:
- Neil Osterweil
Publish date: December 6, 2012
News
- Author:
- Neil Osterweil
Publish date: November 26, 2012
Major Finding: Median time to progression, the primary end point, was 6.9 weeks for patients randomized to tivantinib, compared with 6.0 weeks for...
News
- Author:
- Neil Osterweil
Publish date: November 19, 2012
Major Finding: Nearly a third (32%) of women who underwent accelerated partial-breast irradiation (APBI) with a 3-D conformal technique had cosmet...
News
- Author:
- Neil Osterweil
Publish date: November 16, 2012
News
- Author:
- Neil Osterweil
Publish date: November 16, 2012
News
- Author:
- Neil Osterweil
Publish date: November 13, 2012
Major Finding: Among patients with acute liver failure from acetaminophen, the prevalence of prior bariatric surgery was 25-fold higher than in th...
